rifampicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, rifamycin derivatives	2377	13292-46-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rifampicin rifampin refampicin rifadin rifadine rifaldazine rifaldin rifaprodin	A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Molecular weight: 822.95 Formula: C43H58N4O12 CLOGP: 2.49 LIPINSKI: 3 HAC: 16 HDO: 6 TPSA: 220.15 ALOGS: -4.30 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rifampicin
rifampin
refampicin
rifadin
rifadine
rifaldazine
rifaldin
rifaprodin

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Molecular weight: 822.95
Formula: C43H58N4O12
CLOGP: 2.49
LIPINSKI: 3
HAC: 16
HDO: 6
TPSA: 220.15
ALOGS: -4.30
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O
0.60	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	7 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	70 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.97 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.80 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	1.40 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 21, 1971	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	1258.80	15.76	452	19483	33384	63435703
Paradoxical drug reaction	582.74	15.76	154	19781	3998	63465089
Drug interaction	567.63	15.76	511	19424	228620	63240467
Drug resistance	513.33	15.76	212	19723	22721	63446366
Drug-induced liver injury	405.26	15.76	214	19721	40008	63429079
Eosinophilia	363.94	15.76	166	19769	22590	63446497
Acute hepatic failure	247.54	15.76	119	19816	18208	63450879
Jaundice	195.32	15.76	119	19816	29132	63439955
Tuberculoma of central nervous system	184.61	15.76	38	19897	309	63468778
Rash maculo-papular	168.69	15.76	112	19823	31784	63437303
Acute kidney injury	161.42	15.76	293	19642	263122	63205965
Immune reconstitution inflammatory syndrome	159.24	15.76	63	19872	6021	63463066
Pathogen resistance	142.51	15.76	59	19876	6339	63462748
Tuberculosis	139.94	15.76	69	19866	11142	63457945
Cholestasis	128.83	15.76	92	19843	29342	63439745
Pyrexia	118.69	15.76	370	19565	470108	62998979
Hepatocellular injury	113.93	15.76	83	19852	27298	63441789
Virologic failure	112.95	15.76	36	19899	1826	63467261
Hepatitis	108.36	15.76	94	19841	39694	63429393
Immune reconstitution inflammatory syndrome associated tuberculosis	104.07	15.76	24	19911	346	63468741
Hepatotoxicity	103.90	15.76	89	19846	36952	63432135
Drug ineffective for unapproved indication	102.03	15.76	85	19850	33978	63435109
Hepatic encephalopathy	88.62	15.76	51	19884	11231	63457856
Drug level decreased	84.96	15.76	44	19891	7875	63461212
Product use in unapproved indication	82.56	15.76	177	19758	178903	63290184
Pancreatitis haemorrhagic	75.84	15.76	20	19915	513	63468574
Hepatic cytolysis	74.02	15.76	51	19884	15356	63453731
Pulmonary tuberculosis	69.16	15.76	32	19903	4485	63464602
Optic neuropathy	67.36	15.76	25	19910	2007	63467080
Hidradenitis	65.94	15.76	27	19908	2819	63466268
Thrombocytopenia	64.64	15.76	145	19790	151012	63318075
Hepatic failure	64.15	15.76	67	19868	35589	63433498
Transaminases increased	61.98	15.76	62	19873	31305	63437782
Choroiditis	61.90	15.76	14	19921	184	63468903
Fatigue	59.15	15.76	119	19816	887909	62581178
Renal tubular necrosis	58.67	15.76	40	19895	11838	63457249
Pregnancy with implant contraceptive	57.24	15.76	24	19911	2659	63466428
Type 2 lepra reaction	56.81	15.76	10	19925	30	63469057
Alopecia	56.27	15.76	18	19917	337518	63131569
Pain	55.74	15.76	92	19843	740536	62728551
Glomerulonephritis minimal lesion	53.25	15.76	13	19922	242	63468845
Distributive shock	53.24	15.76	19	19916	1364	63467723
Fall	51.03	15.76	30	19905	392304	63076783
Sinusitis	50.43	15.76	6	19929	226647	63242440
Mechanical urticaria	49.71	15.76	14	19921	462	63468625
Hepatic function abnormal	48.37	15.76	59	19876	37083	63432004
Anticoagulation drug level decreased	48.36	15.76	9	19926	40	63469047
Mycobacterium avium complex infection	47.66	15.76	22	19913	3066	63466021
Labelled drug-drug interaction medication error	45.52	15.76	36	19899	13363	63455724
Cystic fibrosis pancreatic	45.42	15.76	9	19926	59	63469028
Hepatitis fulminant	45.25	15.76	22	19913	3442	63465645
Infusion related reaction	44.78	15.76	11	19924	245510	63223577
Tuberculosis gastrointestinal	43.67	15.76	12	19923	361	63468726
Oligoarthritis	42.87	15.76	13	19922	558	63468529
Nasopharyngitis	41.57	15.76	14	19921	254243	63214844
Contraindicated product administered	41.18	15.76	9	19926	217639	63251448
Vascular purpura	41.12	15.76	16	19919	1462	63467625
Multiple organ dysfunction syndrome	40.95	15.76	68	19867	56684	63412403
Oedematous kidney	40.32	15.76	9	19926	111	63468976
Headache	40.24	15.76	87	19848	633154	62835933
Face oedema	40.02	15.76	40	19895	20172	63448915
Immunosuppressant drug level decreased	40.00	15.76	14	19921	949	63468138
Disseminated tuberculosis	39.85	15.76	19	19916	2848	63466239
Hyperbilirubinaemia	39.73	15.76	31	19904	11283	63457804
Focal dyscognitive seizures	39.51	15.76	19	19916	2902	63466185
Status epilepticus	39.47	15.76	35	19900	15198	63453889
Jarisch-Herxheimer reaction	38.97	15.76	11	19924	366	63468721
Atypical mycobacterial infection	38.18	15.76	14	19921	1086	63468001
Urinary tract infection	37.68	15.76	18	19917	264666	63204421
Aspergillus infection	37.02	15.76	26	19909	8067	63461020
Systemic lupus erythematosus	36.87	15.76	10	19925	208908	63260179
Arthropathy	36.56	15.76	14	19921	234778	63234309
Optic neuritis	36.05	15.76	26	19909	8409	63460678
Abdominal discomfort	35.77	15.76	29	19906	320856	63148231
Constipation	35.71	15.76	13	19922	224930	63244157
Acute respiratory distress syndrome	34.97	15.76	40	19895	23494	63445593
Tubo-ovarian abscess	34.49	15.76	10	19925	367	63468720
Oedematous pancreatitis	34.28	15.76	11	19924	570	63468517
Drug eruption	33.24	15.76	43	19892	28651	63440436
Blood creatine phosphokinase increased	32.78	15.76	44	19891	30386	63438701
Metabolic acidosis	32.51	15.76	54	19881	45015	63424072
Joint swelling	32.48	15.76	33	19902	327633	63141454
Wound	32.44	15.76	6	19929	163257	63305830
Peripheral swelling	32.25	15.76	22	19913	265920	63203167
Eosinophil count increased	32.14	15.76	27	19908	10901	63458186
Hypertransaminasaemia	32.03	15.76	22	19913	6587	63462500
Product dose omission issue	31.75	15.76	17	19918	234296	63234791
Aspartate aminotransferase increased	31.42	15.76	80	19855	90197	63378890
Alanine aminotransferase increased	31.10	15.76	87	19848	103683	63365404
Pain in extremity	31.06	15.76	35	19900	331451	63137636
Linear IgA disease	31.02	15.76	13	19922	1438	63467649
Rheumatoid arthritis	29.46	15.76	22	19913	253797	63215290
Drug ineffective	29.42	15.76	475	19460	1044290	62424797
Dermatitis exfoliative generalised	29.33	15.76	17	19918	3790	63465297
Skin odour abnormal	29.30	15.76	13	19922	1653	63467434
Adrenocortical insufficiency acute	29.06	15.76	13	19922	1685	63467402
Blood alkaline phosphatase increased	29.02	15.76	50	19885	42917	63426170
Eosinophilic pneumonia acute	29.02	15.76	9	19926	417	63468670
Rash morbilliform	28.72	15.76	16	19919	3309	63465778
Skin reaction	28.68	15.76	29	19906	14820	63454267
Mycobacterial infection	28.45	15.76	13	19922	1770	63467317
Generalised onset non-motor seizure	28.41	15.76	5	19930	15	63469072
Discomfort	27.72	15.76	9	19926	167365	63301722
Disseminated intravascular coagulation	27.66	15.76	32	19903	19019	63450068
Chromaturia	27.56	15.76	30	19905	16687	63452400
Palmoplantar pustulosis	27.37	15.76	9	19926	504	63468583
Coagulopathy	27.34	15.76	33	19902	20511	63448576
Bullous haemorrhagic dermatosis	27.19	15.76	6	19929	70	63469017
Anuria	27.01	15.76	26	19909	12525	63456562
Multiple-drug resistance	26.94	15.76	18	19917	5152	63463935
Hepatitis cholestatic	26.68	15.76	20	19915	6858	63462229
Cholestatic liver injury	26.56	15.76	14	19921	2596	63466491
Staphylococcal infection	26.55	15.76	47	19888	41209	63427878
Vomiting	26.45	15.76	280	19655	559337	62909750
Renal impairment	26.40	15.76	74	19861	88281	63380806
Blood bilirubin increased	26.12	15.76	44	19891	37096	63431991
Anti-cyclic citrullinated peptide antibody positive	26.02	15.76	3	19932	116209	63352878
Alagille syndrome	25.50	15.76	4	19931	4	63469083
Premature labour	25.22	15.76	25	19910	12479	63456608
Therapy naive	25.20	15.76	5	19930	33	63469054
Agranulocytosis	25.04	15.76	35	19900	25099	63443988
Contusion	24.97	15.76	8	19927	150036	63319051
Crystalluria	24.92	15.76	8	19927	415	63468672
Tubulointerstitial nephritis	24.91	15.76	31	19904	19872	63449215
Off label use	24.59	15.76	321	19614	674141	62794946
Pigment nephropathy	24.59	15.76	5	19930	38	63469049
Purpura non-thrombocytopenic	24.36	15.76	6	19929	116	63468971
Vanishing bile duct syndrome	24.24	15.76	9	19926	723	63468364
Clostridium difficile colitis	24.10	15.76	31	19904	20538	63448549
Lymphadenopathy	23.71	15.76	43	19892	38415	63430672
Hepatitis toxic	23.68	15.76	14	19921	3239	63465848
Breast discomfort	23.53	15.76	8	19927	497	63468590
Dizziness	23.35	15.76	64	19871	429861	63039226
Respiratory symptom	23.31	15.76	14	19921	3333	63465754
Pancytopenia	23.13	15.76	75	19860	96858	63372229
Granuloma	22.90	15.76	17	19918	5744	63463343
Toxic skin eruption	22.79	15.76	24	19911	12861	63456226
Intentional product use issue	22.78	15.76	6	19929	127886	63341201
Exfoliative rash	22.70	15.76	13	19922	2834	63466253
Haemolysis	22.59	15.76	18	19917	6750	63462337
Type IV hypersensitivity reaction	22.49	15.76	13	19922	2885	63466202
Death	22.44	15.76	53	19882	374328	63094759
Mastitis bacterial	22.30	15.76	5	19930	63	63469024
Human herpesvirus 6 infection	22.24	15.76	13	19922	2944	63466143
Dyspnoea	22.04	15.76	120	19815	661193	62807894
Pericarditis	21.92	15.76	7	19928	131572	63337515
Hydrocephalus	21.88	15.76	16	19919	5284	63463803
Erythema multiforme	21.76	15.76	21	19914	10148	63458939
Toxic optic neuropathy	21.57	15.76	6	19929	189	63468898
Liver injury	21.43	15.76	54	19881	60466	63408621
Leukopenia	21.41	15.76	63	19872	77227	63391860
Enterovirus infection	21.40	15.76	9	19926	1005	63468082
Limbal swelling	21.28	15.76	4	19931	19	63469068
Condition aggravated	21.24	15.76	206	19729	402011	63067076
Mixed liver injury	21.16	15.76	15	19920	4720	63464367
Latent tuberculosis	20.96	15.76	12	19923	2615	63466472
Anticoagulation drug level below therapeutic	20.76	15.76	8	19927	712	63468375
Immune system disorder	20.46	15.76	20	19915	9814	63459273
Cryptococcosis	20.25	15.76	9	19926	1148	63467939
Haemolytic anaemia	19.97	15.76	20	19915	10105	63458982
Swelling	19.88	15.76	35	19900	275343	63193744
Skin lesion	19.77	15.76	35	19900	30686	63438401
Purpura	19.77	15.76	21	19914	11364	63457723
Nosocomial infection	19.72	15.76	10	19925	1711	63467376
Unintended pregnancy	19.70	15.76	16	19919	6163	63462924
Nephropathy toxic	19.20	15.76	19	19916	9460	63459627
Tuberculosis of eye	19.17	15.76	4	19931	35	63469052
Folate deficiency	18.93	15.76	11	19924	2464	63466623
Ototoxicity	18.85	15.76	9	19926	1353	63467734
White matter lesion	18.82	15.76	10	19925	1885	63467202
Hepatic necrosis	18.71	15.76	15	19920	5672	63463415
Back pain	18.68	15.76	34	19901	264111	63204976
Endocarditis	18.57	15.76	15	19920	5735	63463352
Bronchitis	18.53	15.76	8	19927	124927	63344160
Acute generalised exanthematous pustulosis	18.44	15.76	20	19915	11079	63458008
Synovitis	18.30	15.76	19	19916	186899	63282188
Anxiety	18.23	15.76	25	19910	217516	63251571
Epstein-Barr virus test positive	18.22	15.76	7	19928	618	63468469
Orbital infection	18.02	15.76	4	19931	48	63469039
Post treatment Lyme disease syndrome	17.91	15.76	3	19932	6	63469081
Eyelid oedema	17.61	15.76	19	19916	10460	63458627
Pancreatitis	17.61	15.76	44	19891	49011	63420076
Hyperleukocytosis	17.59	15.76	7	19928	679	63468408
Muscle spasms	17.51	15.76	14	19921	156136	63312951
Gamma-glutamyltransferase increased	17.23	15.76	35	19900	33996	63435091
Rebound effect	17.20	15.76	13	19922	4513	63464574
Bile duct necrosis	17.04	15.76	3	19932	9	63469078
Rheumatoid factor positive	16.98	15.76	3	19932	84403	63384684
Wound secretion	16.98	15.76	13	19922	4601	63464486
Visual acuity reduced	16.88	15.76	27	19908	21799	63447288
Type 1 lepra reaction	16.80	15.76	3	19932	10	63469077
Neutropenia	16.72	15.76	103	19832	174902	63294185
Pneumatosis intestinalis	16.56	15.76	10	19925	2403	63466684
Disseminated cytomegaloviral infection	16.53	15.76	5	19930	213	63468874
Loss of personal independence in daily activities	16.52	15.76	5	19930	97285	63371802
Encephalopathy	16.42	15.76	37	19898	38583	63430504
Scar excision	16.36	15.76	4	19931	75	63469012
Glomerular filtration rate abnormal	16.22	15.76	7	19928	832	63468255
Acid fast bacilli infection	16.16	15.76	4	19931	79	63469008
Skin hyperpigmentation	16.13	15.76	14	19921	5907	63463180
Cheilitis	16.04	15.76	12	19923	4101	63464986
International normalised ratio abnormal	16.01	15.76	11	19924	3293	63465794
Lower respiratory tract infection	15.95	15.76	11	19924	132296	63336791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	1047.58	16.09	270	21428	3081	34932152
Drug reaction with eosinophilia and systemic symptoms	909.35	16.09	432	21266	32580	34902653
Drug-induced liver injury	409.93	16.09	243	21455	28589	34906644
Drug resistance	364.55	16.09	217	21481	25710	34909523
Immune reconstitution inflammatory syndrome	350.22	16.09	149	21549	8610	34926623
Drug interaction	309.03	16.09	523	21175	225423	34709810
Hepatotoxicity	243.94	16.09	157	21541	21328	34913905
Jaundice	235.58	16.09	179	21519	31703	34903530
Rash maculo-papular	197.60	16.09	154	21544	28297	34906936
Eosinophilia	193.18	16.09	147	21551	26075	34909158
Immune reconstitution inflammatory syndrome associated tuberculosis	163.15	16.09	41	21657	417	34934816
Drug level decreased	146.12	16.09	79	21619	7767	34927466
Acute kidney injury	139.43	16.09	460	21238	304528	34630705
Type 2 lepra reaction	135.53	16.09	30	21668	165	34935068
Hypoprothrombinaemia	130.14	16.09	33	21665	349	34934884
Hepatocellular injury	122.16	16.09	105	21593	22106	34913127
Cholestasis	112.23	16.09	109	21589	26839	34908394
Optic neuropathy	111.45	16.09	43	21655	1922	34933311
Tubulointerstitial nephritis	108.78	16.09	96	21602	20928	34914305
Thrombocytopenia	108.28	16.09	274	21424	155973	34779260
Tuberculosis	100.55	16.09	64	21634	8513	34926720
Pyrexia	95.83	16.09	434	21264	332579	34602654
Mycobacterial infection	93.56	16.09	40	21658	2334	34932899
Hepatitis	90.84	16.09	92	21606	23812	34911421
Cardiac valve vegetation	89.92	16.09	26	21672	465	34934768
Condition aggravated	86.68	16.09	289	21409	191907	34743326
Immune system disorder	85.59	16.09	48	21650	5067	34930166
Drug ineffective	85.25	16.09	528	21170	456223	34479010
Vascular purpura	83.67	16.09	34	21664	1744	34933489
Pathogen resistance	82.95	16.09	59	21639	9423	34925810
Death	78.65	16.09	79	21619	397970	34537263
Tuberculoma of central nervous system	76.26	16.09	20	21678	244	34934989
Jarisch-Herxheimer reaction	72.56	16.09	23	21675	568	34934665
Fall	69.39	16.09	20	21678	202865	34732368
Drug ineffective for unapproved indication	61.93	16.09	75	21623	23640	34911593
Vitamin K deficiency	61.71	16.09	17	21681	253	34934980
Granuloma	61.26	16.09	33	21665	3218	34932015
Alveolar lung disease	59.99	16.09	18	21680	368	34934865
Eosinophilic pneumonia	58.97	16.09	33	21665	3468	34931765
Hydrocephalus	58.74	16.09	38	21660	5194	34930039
Hepatic failure	57.83	16.09	88	21610	34443	34900790
Multiple-drug resistance	56.25	16.09	37	21661	5202	34930031
Treatment failure	54.19	16.09	101	21597	46596	34888637
Tuberculosis of central nervous system	51.81	16.09	14	21684	193	34935040
Liver function test abnormal	51.76	16.09	79	21619	30995	34904238
Pulmonary interstitial emphysema syndrome	50.59	16.09	17	21681	507	34934726
Fatigue	50.58	16.09	96	21602	370557	34564676
Type 1 lepra reaction	50.01	16.09	10	21688	30	34935203
Lymphadenopathy	49.74	16.09	74	21624	28389	34906844
Purpura	49.20	16.09	45	21653	10266	34924967
Completed suicide	48.98	16.09	3	21695	98165	34837068
Hypovitaminosis	48.34	16.09	17	21681	583	34934650
Hepatic function abnormal	47.83	16.09	93	21605	44270	34890963
Optic neuritis	47.78	16.09	29	21669	3545	34931688
Skin disorder	47.56	16.09	50	21648	13505	34921728
Linear IgA disease	46.82	16.09	22	21676	1604	34933629
Mycobacterium avium complex infection	45.95	16.09	25	21673	2486	34932747
Constipation	45.89	16.09	14	21684	136968	34798265
Myocardial infarction	45.09	16.09	10	21688	121075	34814158
Pulmonary tuberculosis	44.88	16.09	31	21667	4723	34930510
Febrile neutropenia	44.05	16.09	15	21683	136834	34798399
Immune thrombocytopenia	43.78	16.09	40	21658	9112	34926121
Acute hepatic failure	42.55	16.09	48	21650	14026	34921207
Meningitis tuberculous	42.48	16.09	16	21682	669	34934564
Drug abuse	41.62	16.09	6	21692	99090	34836143
Thalamic infarction	40.44	16.09	16	21682	765	34934468
Granulomatous liver disease	40.41	16.09	15	21683	602	34934631
Product use in unapproved indication	39.60	16.09	161	21537	117338	34817895
Hypersensitivity vasculitis	39.37	16.09	25	21673	3310	34931923
Haemolytic anaemia	39.19	16.09	40	21658	10439	34924794
Anticoagulation drug level decreased	38.99	16.09	10	21688	111	34935122
Diaphragmatic injury	37.83	16.09	10	21688	126	34935107
Transaminases increased	37.54	16.09	63	21635	26760	34908473
Toxic skin eruption	36.43	16.09	40	21658	11345	34923888
Tuberculosis of eye	36.14	16.09	8	21690	44	34935189
Pneumonia	34.51	16.09	113	21585	362514	34572719
Cross sensitivity reaction	34.46	16.09	17	21681	1380	34933853
Diffuse alveolar damage	34.12	16.09	20	21678	2294	34932939
Splenic embolism	34.07	16.09	10	21688	189	34935044
Dizziness	33.95	16.09	52	21646	218469	34716764
Product dose omission issue	32.31	16.09	17	21681	119694	34815539
Ocular toxicity	32.30	16.09	10	21688	228	34935005
Hidradenitis	32.27	16.09	15	21683	1067	34934166
Ototoxicity	32.09	16.09	18	21680	1899	34933334
Aortic valve prolapse	32.07	16.09	6	21692	11	34935222
Hepatic cytolysis	31.73	16.09	42	21656	14454	34920779
Cutaneous vasculitis	31.58	16.09	24	21674	4239	34930994
Sideroblastic anaemia	31.47	16.09	10	21688	249	34934984
Oliguria	31.36	16.09	32	21666	8348	34926885
Eosinophilic pneumonia acute	31.19	16.09	12	21686	532	34934701
Mycobacterium abscessus infection	31.19	16.09	12	21686	532	34934701
Hyperbilirubinaemia	31.17	16.09	45	21653	16798	34918435
Drug eruption	30.91	16.09	49	21649	19849	34915384
Cardiac failure congestive	30.74	16.09	7	21691	83263	34851970
Pain	30.56	16.09	50	21648	204625	34730608
Generalised oedema	30.38	16.09	38	21660	12370	34922863
Vascular pseudoaneurysm thrombosis	30.30	16.09	7	21691	48	34935185
Immunosuppressant drug level decreased	30.16	16.09	15	21683	1239	34933994
Dermatitis exfoliative generalised	29.98	16.09	22	21676	3685	34931548
Hepatic encephalopathy	29.79	16.09	41	21657	14644	34920589
Disseminated tuberculosis	29.75	16.09	18	21680	2187	34933046
Diarrhoea	29.67	16.09	133	21565	389779	34545454
Malignant neoplasm progression	29.47	16.09	9	21689	88037	34847196
Atrial fibrillation	29.35	16.09	20	21678	122373	34812860
Toxic epidermal necrolysis	29.17	16.09	50	21648	21596	34913637
Vitamin B1 decreased	28.85	16.09	10	21688	328	34934905
Coagulopathy	28.38	16.09	47	21651	19742	34915491
Central nervous system vasculitis	28.37	16.09	11	21687	498	34934735
Endocarditis	28.33	16.09	27	21671	6484	34928749
Lymphopenia	27.86	16.09	42	21656	16293	34918940
Hepatic enzyme increased	27.44	16.09	69	21629	39011	34896222
Leukopenia	26.87	16.09	93	21605	62763	34872470
Dyspnoea	26.61	16.09	132	21566	376650	34558583
Mycobacterium tuberculosis complex test positive	26.44	16.09	14	21684	1318	34933915
Cat scratch disease	26.11	16.09	8	21690	176	34935057
Type III immune complex mediated reaction	25.77	16.09	9	21689	302	34934931
Lymph node tuberculosis	25.74	16.09	10	21688	455	34934778
Atypical mycobacterial infection	25.46	16.09	12	21686	881	34934352
Coagulation factor X level decreased	25.26	16.09	5	21693	14	34935219
Drug level abnormal	25.18	16.09	8	21690	199	34935034
Hepatic necrosis	25.15	16.09	20	21678	3774	34931459
Stevens-Johnson syndrome	25.04	16.09	43	21655	18596	34916637
Shock haemorrhagic	25.01	16.09	33	21665	11321	34923912
Petechiae	24.92	16.09	30	21668	9388	34925845
Encephalopathy	24.42	16.09	62	21636	35257	34899976
Autoimmune haemolytic anaemia	24.18	16.09	21	21677	4475	34930758
Anxiety	24.17	16.09	16	21682	99412	34835821
Brain abscess	24.05	16.09	18	21680	3107	34932126
Splenic abscess	23.97	16.09	9	21689	373	34934860
Tuberculoid leprosy	23.96	16.09	6	21692	60	34935173
Nasopharyngitis	23.68	16.09	7	21691	69961	34865272
Bone tuberculosis	23.41	16.09	9	21689	398	34934835
Infective aneurysm	23.20	16.09	10	21688	595	34934638
Tendon disorder	23.11	16.09	17	21681	2858	34932375
Blood pressure increased	23.05	16.09	13	21685	88089	34847144
Jaundice cholestatic	23.02	16.09	21	21677	4773	34930460
Bradycardia	23.01	16.09	9	21689	75409	34859824
Atypical mycobacterium test positive	22.98	16.09	5	21693	25	34935208
Infusion related reaction	22.77	16.09	3	21695	53054	34882179
Candida infection	22.67	16.09	40	21658	17675	34917558
Thrombocytopenic purpura	22.32	16.09	12	21686	1165	34934068
Urinary tract inflammation	22.23	16.09	7	21691	169	34935064
Unmasking of previously unidentified disease	22.18	16.09	11	21687	903	34934330
Labelled drug-drug interaction medication error	22.12	16.09	36	21662	14903	34920330
Malaise	21.22	16.09	53	21645	185772	34749461
Dehydration	21.06	16.09	30	21668	129939	34805294
Pulmonary sequestration	20.97	16.09	5	21693	40	34935193
Staphylococcal bacteraemia	20.87	16.09	26	21672	8426	34926807
Leprosy	20.77	16.09	6	21692	107	34935126
Eosinophilic myocarditis	20.76	16.09	9	21689	543	34934690
Antimicrobial susceptibility test resistant	20.55	16.09	8	21690	366	34934867
Vasculitis necrotising	20.29	16.09	10	21688	810	34934423
Asthenia	20.24	16.09	81	21617	245170	34690063
Cerebrovascular accident	20.14	16.09	14	21684	84797	34850436
Coronary artery disease	20.09	16.09	3	21695	48302	34886931
Staphylococcal infection	20.09	16.09	55	21643	32705	34902528
Tuberculosis gastrointestinal	19.99	16.09	7	21691	237	34934996
Insomnia	19.98	16.09	21	21677	103886	34831347
Lactic acidosis	19.97	16.09	57	21641	34715	34900518
Pulmonary eosinophilia	19.85	16.09	7	21691	242	34934991
Hyperammonaemia	19.73	16.09	22	21676	6345	34928888
Hepatorenal syndrome	19.72	16.09	15	21683	2651	34932582
Pyroglutamic acidosis	19.54	16.09	8	21690	418	34934815
Depression	19.38	16.09	19	21679	97079	34838154
Choroiditis	19.24	16.09	11	21687	1204	34934029
Dilatation intrahepatic duct acquired	19.14	16.09	5	21693	60	34935173
Pulmonary cavitation	19.10	16.09	10	21688	920	34934313
Adrenocortical insufficiency acute	18.90	16.09	12	21686	1588	34933645
Rash	18.77	16.09	216	21482	222536	34712697
Feeling abnormal	18.55	16.09	8	21690	63227	34872006
Neutropenia	18.49	16.09	163	21535	156615	34778618
Conductive deafness	18.35	16.09	7	21691	303	34934930
Splenic infarction	18.35	16.09	13	21685	2062	34933171
Muscle spasms	18.31	16.09	12	21686	74989	34860244
Lichenoid keratosis	18.31	16.09	14	21684	2494	34932739
Renal tubular necrosis	18.28	16.09	34	21664	15646	34919587
Syncope	18.13	16.09	18	21680	91433	34843800
Headache	18.02	16.09	64	21634	200571	34734662
Dysbiosis	17.95	16.09	8	21690	516	34934717
Rash morbilliform	17.79	16.09	15	21683	3072	34932161
Axonal neuropathy	17.72	16.09	10	21688	1067	34934166
Agranulocytosis	17.71	16.09	43	21655	23778	34911455
Malabsorption from administration site	17.70	16.09	5	21693	82	34935151
Weight increased	17.66	16.09	19	21679	93014	34842219
Implant site infection	17.61	16.09	10	21688	1080	34934153
White blood cell count decreased	17.56	16.09	20	21678	95425	34839808
Protrusion tongue	17.42	16.09	6	21692	193	34935040
C-reactive protein increased	17.30	16.09	73	21625	54025	34881208
CD4/CD8 ratio decreased	17.24	16.09	4	21694	28	34935205
Trisomy 21	17.08	16.09	8	21690	579	34934654
Marrow hyperplasia	17.01	16.09	10	21688	1153	34934080
Pulmonary granuloma	16.90	16.09	11	21687	1519	34933714
COVID-19	16.87	16.09	14	21684	77536	34857697
Renal atrophy	16.84	16.09	10	21688	1175	34934058
Tuberculous pleurisy	16.83	16.09	7	21691	381	34934852
Testicular mass	16.81	16.09	5	21693	99	34935134
Influenza	16.75	16.09	5	21693	49661	34885572
Hypertransaminasaemia	16.74	16.09	19	21679	5587	34929646
Hemianopia heteronymous	16.56	16.09	4	21694	34	34935199
Neuropsychiatric symptoms	16.56	16.09	9	21689	893	34934340
Erythrodermic psoriasis	16.51	16.09	9	21689	898	34934335
Oral candidiasis	16.35	16.09	28	21670	12082	34923151
Chronic allograft nephropathy	16.29	16.09	10	21688	1247	34933986

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	2045.51	14.21	867	38332	63377	79641812
Paradoxical drug reaction	1549.69	14.21	411	38788	6774	79698415
Drug-induced liver injury	762.06	14.21	448	38751	65669	79639520
Drug interaction	711.41	14.21	943	38256	414240	79290949
Drug resistance	610.49	14.21	332	38867	41881	79663308
Eosinophilia	539.99	14.21	314	38885	45031	79660158
Immune reconstitution inflammatory syndrome	480.07	14.21	199	39000	13642	79691547
Jaundice	443.71	14.21	294	38905	53055	79652134
Rash maculo-papular	365.30	14.21	266	38933	55812	79649377
Hepatotoxicity	337.68	14.21	245	38954	51107	79654082
Acute kidney injury	312.30	14.21	746	38453	518658	79186531
Acute hepatic failure	269.91	14.21	174	39025	29939	79675250
Immune reconstitution inflammatory syndrome associated tuberculosis	269.68	14.21	66	39133	770	79704419
Drug level decreased	249.81	14.21	128	39071	14274	79690915
Cholestasis	234.98	14.21	199	39000	51910	79653279
Tuberculoma of central nervous system	234.09	14.21	55	39144	532	79704657
Hepatocellular injury	227.52	14.21	188	39011	47405	79657784
Tuberculosis	223.60	14.21	121	39078	15077	79690112
Pyrexia	211.79	14.21	772	38427	677937	79027252
Thrombocytopenia	180.83	14.21	401	38798	264858	79440331
Type 2 lepra reaction	177.71	14.21	37	39162	191	79704998
Optic neuropathy	165.88	14.21	63	39136	3421	79701768
Hepatitis	155.33	14.21	163	39036	55564	79649625
Pathogen resistance	138.75	14.21	87	39112	14255	79690934
Tubulointerstitial nephritis	136.51	14.21	128	39071	38107	79667082
Hypoprothrombinaemia	134.30	14.21	37	39162	705	79704484
Vascular purpura	126.13	14.21	50	39149	3048	79702141
Fall	123.31	14.21	43	39156	487586	79217603
Hepatic failure	121.24	14.21	150	39049	61062	79644127
Drug ineffective	118.92	14.21	921	38278	1079992	78625197
Drug ineffective for unapproved indication	113.65	14.21	133	39066	51105	79654084
Hepatic encephalopathy	112.41	14.21	94	39105	24072	79681117
Pulmonary tuberculosis	111.18	14.21	61	39138	7804	79697385
Immune system disorder	109.45	14.21	68	39131	10961	79694228
Fatigue	109.35	14.21	181	39018	929546	78775643
Mycobacterial infection	108.08	14.21	47	39152	3621	79701568
Hepatic function abnormal	106.22	14.21	154	39045	72953	79632236
Pain	100.63	14.21	119	39080	703683	79001506
Completed suicide	100.06	14.21	5	39194	245762	79459427
Jarisch-Herxheimer reaction	99.31	14.21	31	39168	926	79704263
Hepatic cytolysis	97.11	14.21	91	39108	27060	79678129
Cardiac valve vegetation	96.34	14.21	30	39169	889	79704300
Optic neuritis	82.78	14.21	54	39145	9466	79695723
Anticoagulation drug level decreased	82.19	14.21	19	39180	170	79705019
Headache	81.71	14.21	122	39077	653650	79051539
Lymphadenopathy	81.49	14.21	115	39084	53132	79652057
Transaminases increased	81.05	14.21	113	39086	51630	79653559
Nasopharyngitis	80.33	14.21	14	39185	253867	79451322
Infusion related reaction	79.05	14.21	10	39189	230227	79474962
Mycobacterium avium complex infection	77.20	14.21	40	39159	4560	79700629
Constipation	76.73	14.21	22	39177	283028	79422161
Linear IgA disease	75.89	14.21	35	39164	3097	79702092
Granuloma	74.45	14.21	48	39151	8249	79696940
Death	74.43	14.21	102	39097	566412	79138777
Hidradenitis	73.70	14.21	34	39165	3010	79702179
Type 1 lepra reaction	72.54	14.21	14	39185	45	79705144
Hyperbilirubinaemia	72.40	14.21	74	39125	24444	79680745
Condition aggravated	69.24	14.21	452	38747	500672	79204517
Eosinophilic pneumonia	69.09	14.21	39	39160	5271	79699918
Hydrocephalus	68.99	14.21	47	39152	8853	79696336
Purpura	68.97	14.21	65	39134	19462	79685727
Immunosuppressant drug level decreased	66.72	14.21	28	39171	1976	79703213
Disseminated tuberculosis	66.28	14.21	35	39164	4148	79701041
Choroiditis	65.84	14.21	25	39174	1356	79703833
Multiple-drug resistance	64.70	14.21	45	39154	8763	79696426
Haemolytic anaemia	64.25	14.21	60	39139	17760	79687429
Renal tubular necrosis	64.03	14.21	70	39129	24969	79680220
Dizziness	64.02	14.21	100	39099	526341	79178848
Meningitis tuberculous	61.76	14.21	23	39176	1182	79704007
Alopecia	60.84	14.21	19	39180	231336	79473853
Product dose omission issue	60.49	14.21	23	39176	247514	79457675
Atypical mycobacterial infection	60.20	14.21	25	39174	1718	79703471
Rheumatoid arthritis	58.75	14.21	15	39184	208455	79496734
Product use in unapproved indication	58.53	14.21	261	38938	250098	79455091
Drug abuse	58.50	14.21	6	39193	162685	79542504
Pancreatitis haemorrhagic	58.26	14.21	20	39179	810	79704379
Dermatitis exfoliative generalised	57.94	14.21	39	39160	7202	79697987
Alveolar lung disease	57.00	14.21	18	39181	559	79704630
Coagulopathy	56.93	14.21	79	39120	35927	79669262
Joint swelling	56.66	14.21	36	39163	288610	79416579
Eosinophilic pneumonia acute	56.43	14.21	21	39178	1077	79704112
Drug eruption	55.88	14.21	87	39112	43848	79661341
Peripheral swelling	55.19	14.21	32	39167	269585	79435604
Dyspnoea	55.03	14.21	226	38973	856799	78848390
Pulmonary interstitial emphysema syndrome	54.52	14.21	17	39182	506	79704683
Liver function test abnormal	53.74	14.21	106	39093	64369	79640820
Distributive shock	52.81	14.21	26	39173	2661	79702528
Toxic skin eruption	51.31	14.21	59	39140	22234	79682955
Tuberculosis of central nervous system	51.29	14.21	16	39183	477	79704712
Ototoxicity	50.76	14.21	27	39172	3247	79701942
Urinary tract infection	50.19	14.21	37	39162	274475	79430714
Tuberculosis gastrointestinal	48.89	14.21	16	39183	558	79704631
Labelled drug-drug interaction medication error	48.79	14.21	64	39135	27586	79677603
Leukopenia	48.00	14.21	146	39053	116367	79588822
Pain in extremity	47.44	14.21	66	39133	364472	79340717
Adrenocortical insufficiency acute	46.91	14.21	25	39174	3018	79702171
Eosinophil count increased	45.80	14.21	49	39150	17056	79688133
Arthropathy	45.75	14.21	15	39184	177096	79528093
Abdominal discomfort	45.56	14.21	34	39165	250693	79454496
Vitamin K deficiency	45.16	14.21	16	39183	712	79704477
Mechanical urticaria	44.63	14.21	14	39185	425	79704764
Myocardial infarction	43.51	14.21	18	39181	184111	79521078
Lymph node tuberculosis	43.50	14.21	17	39182	997	79704192
Status epilepticus	42.70	14.21	57	39142	24984	79680205
Encephalopathy	42.56	14.21	99	39100	67298	79637891
Insomnia	42.33	14.21	35	39164	245135	79460054
Granulomatous liver disease	42.30	14.21	18	39181	1315	79703874
Malignant neoplasm progression	41.91	14.21	8	39191	135982	79569207
Rash morbilliform	41.88	14.21	30	39169	6120	79699069
Pneumonia	41.75	14.21	175	39024	660071	79045118
Disseminated intravascular coagulation	41.49	14.21	68	39131	35774	79669415
Hepatic necrosis	41.49	14.21	35	39164	9065	79696124
Cystic fibrosis pancreatic	41.40	14.21	9	39190	59	79705130
Hypovitaminosis	41.37	14.21	17	39182	1137	79704052
Anxiety	41.06	14.21	37	39162	248475	79456714
Hypertransaminasaemia	40.79	14.21	39	39160	11885	79693304
Glomerulonephritis minimal lesion	40.26	14.21	15	39184	772	79704417
Diarrhoea	40.18	14.21	261	38938	880228	78824961
Diaphragmatic injury	40.15	14.21	10	39189	126	79705063
Wound	39.97	14.21	5	39194	116174	79589015
Agranulocytosis	39.92	14.21	76	39123	44954	79660235
Multiple organ dysfunction syndrome	39.91	14.21	140	39059	120106	79585083
Febrile neutropenia	39.85	14.21	33	39166	230966	79474223
Arthralgia	39.68	14.21	146	39053	571657	79133532
Bronchitis	39.60	14.21	8	39191	130636	79574553
Hepatitis fulminant	39.59	14.21	31	39168	7231	79697958
Metabolic acidosis	39.36	14.21	109	39090	82420	79622769
Thalamic infarction	39.33	14.21	17	39182	1290	79703899
Tuberculosis of eye	39.09	14.21	9	39190	79	79705110
Face oedema	39.00	14.21	58	39141	28078	79677111
Skin disorder	38.75	14.21	64	39135	33879	79671310
Hypersensitivity vasculitis	38.63	14.21	30	39169	6913	79698276
Brain abscess	38.10	14.21	26	39173	4910	79700279
Cholestatic liver injury	38.07	14.21	26	39173	4915	79700274
Immune thrombocytopenia	37.45	14.21	45	39154	17760	79687429
Influenza	37.13	14.21	9	39190	129597	79575592
Mycobacterium abscessus infection	37.12	14.21	16	39183	1206	79703983
Pregnancy with implant contraceptive	36.59	14.21	18	39181	1838	79703351
Splenic embolism	35.75	14.21	10	39189	202	79704987
Cardiac failure congestive	35.15	14.21	13	39186	142389	79562800
Type IV hypersensitivity reaction	35.12	14.21	23	39176	4058	79701131
Rash	35.04	14.21	436	38763	577922	79127267
Jaundice cholestatic	35.03	14.21	35	39164	11249	79693940
Alanine aminotransferase increased	34.63	14.21	165	39034	162405	79542784
Neutropenia	34.57	14.21	251	38948	287459	79417730
Liver injury	34.48	14.21	82	39117	56532	79648657
Contusion	34.41	14.21	15	39184	148761	79556428
Renal impairment	34.24	14.21	161	39038	157622	79547567
Oligoarthritis	34.13	14.21	13	39186	711	79704478
Oliguria	33.94	14.21	41	39158	16268	79688921
Autoimmune haemolytic anaemia	33.69	14.21	30	39169	8350	79696839
Stevens-Johnson syndrome	33.37	14.21	65	39134	39101	79666088
Contraindicated product administered	33.22	14.21	18	39181	157520	79547669
Endocarditis	33.14	14.21	33	39166	10564	79694625
Blood bilirubin increased	33.10	14.21	89	39110	66143	79639046
Sideroblastic anaemia	32.96	14.21	10	39189	271	79704918
Staphylococcal bacteraemia	32.71	14.21	35	39164	12183	79693006
Aortic valve prolapse	32.49	14.21	6	39193	14	79705175
Hepatitis cholestatic	32.45	14.21	37	39162	13815	79691374
Feeling abnormal	32.41	14.21	19	39180	159180	79546009
Tuberculoid leprosy	31.89	14.21	8	39191	104	79705085
Ocular toxicity	31.66	14.21	13	39186	868	79704321
Generalised oedema	31.62	14.21	48	39151	23661	79681528
Weight increased	31.50	14.21	55	39144	277331	79427858
Muscle spasms	31.34	14.21	24	39175	174706	79530483
Vascular pseudoaneurysm thrombosis	31.20	14.21	7	39192	54	79705135
Intentional product use issue	31.18	14.21	18	39181	152094	79553095
Intentional overdose	31.06	14.21	7	39192	105953	79599236
Oedematous kidney	31.03	14.21	9	39190	208	79704981
Tubo-ovarian abscess	31.00	14.21	10	39189	333	79704856
Asthma	30.65	14.21	14	39185	135081	79570108
Skin lesion	30.38	14.21	65	39134	41779	79663410
Diffuse alveolar damage	30.25	14.21	20	39179	3584	79701605
Mixed liver injury	30.21	14.21	27	39172	7551	79697638
Lymphopenia	30.14	14.21	54	39145	30503	79674686
Anti-cyclic citrullinated peptide antibody positive	30.05	14.21	3	39196	83140	79622049
Aspartate aminotransferase increased	29.73	14.21	141	39058	138500	79566689
Impaired healing	29.60	14.21	4	39195	87651	79617538
Bone tuberculosis	29.47	14.21	11	39188	569	79704620
Dehydration	29.29	14.21	48	39151	248139	79457050
Visual acuity reduced	28.96	14.21	52	39147	29417	79675772
Lactic acidosis	28.81	14.21	88	39111	70271	79634918
Staphylococcal infection	28.79	14.21	78	39121	58217	79646972
Toxic epidermal necrolysis	28.71	14.21	66	39133	44515	79660674
Pemphigus	28.36	14.21	7	39192	99575	79605614
Focal dyscognitive seizures	28.30	14.21	19	39180	3493	79701696
Cerebrovascular accident	28.27	14.21	21	39178	155271	79549918
Oedematous pancreatitis	28.13	14.21	13	39186	1155	79704034
Hepatitis toxic	28.12	14.21	22	39177	5125	79700064
Back pain	28.03	14.21	68	39131	304112	79401077
Thrombosis	28.02	14.21	4	39195	84096	79621093
Treatment failure	28.00	14.21	161	39038	170325	79534864
Memory impairment	27.92	14.21	10	39189	111724	79593465
Blood cholesterol increased	27.85	14.21	4	39195	83716	79621473
COVID-19	27.84	14.21	22	39177	157652	79547537
Stomatitis	27.83	14.21	19	39180	146738	79558451
Injection site erythema	27.80	14.21	3	39196	78194	79626995
Mycobacterium tuberculosis complex test positive	27.16	14.21	17	39182	2775	79702414
Discomfort	27.00	14.21	14	39185	125603	79579586
Lower respiratory tract infection	26.90	14.21	15	39184	129205	79575984
Pulmonary eosinophilia	26.85	14.21	11	39188	730	79704459
Blood pressure increased	26.74	14.21	39	39160	211321	79493868
Exfoliative rash	26.68	14.21	19	39180	3840	79701349
Pigment nephropathy	26.66	14.21	6	39193	47	79705142
Petechiae	26.53	14.21	41	39158	20524	79684665
Pancytopenia	26.23	14.21	155	39044	165590	79539599
Drug level below therapeutic	26.18	14.21	28	39171	9742	79695447
Vitamin B1 decreased	26.15	14.21	10	39189	553	79704636
Loss of personal independence in daily activities	25.94	14.21	9	39190	102571	79602618
Central nervous system vasculitis	25.82	14.21	13	39186	1395	79703794
Synovitis	25.42	14.21	22	39177	150712	79554477
Chest pain	25.31	14.21	64	39135	282240	79422949
Splenic infarction	25.24	14.21	18	39181	3646	79701543
Syncope	24.83	14.21	31	39168	179418	79525771
Acute generalised exanthematous pustulosis	24.53	14.21	36	39163	17218	79687971
Cutaneous vasculitis	24.53	14.21	25	39174	8227	79696962
Asthenia	24.12	14.21	150	39049	511539	79193650
Bradycardia	23.82	14.21	19	39180	135538	79569651
Depression	23.69	14.21	44	39155	216746	79488443
Pulmonary sequestration	23.67	14.21	5	39194	28	79705161
Infective aneurysm	23.60	14.21	11	39188	997	79704192
Lymphadenitis	23.51	14.21	19	39180	4636	79700553
Cachexia	23.29	14.21	28	39171	11055	79694134
Virologic failure	23.08	14.21	18	39181	4173	79701016
Vomiting	23.07	14.21	457	38742	665371	79039818
Hemianopia heteronymous	23.00	14.21	6	39193	92	79705097
Injury	22.96	14.21	5	39194	77491	79627698
Bullous haemorrhagic dermatosis	22.88	14.21	6	39193	94	79705095
Cross sensitivity reaction	22.77	14.21	17	39182	3695	79701494
Transplant rejection	22.66	14.21	37	39162	19400	79685789
Liver transplant rejection	22.48	14.21	16	39183	3232	79701957
Palmoplantar pustulosis	22.31	14.21	9	39190	574	79704615
Dermatitis exfoliative	22.17	14.21	27	39172	10802	79694387
Splenic abscess	22.12	14.21	9	39190	587	79704602
Cat scratch disease	21.83	14.21	8	39191	393	79704796
Shock haemorrhagic	21.80	14.21	37	39162	20023	79685166
Fluid retention	21.73	14.21	4	39195	69805	79635384
Eosinophilic myocarditis	21.59	14.21	11	39188	1211	79703978
Migraine	21.57	14.21	8	39191	87485	79617704
Conductive deafness	21.56	14.21	7	39192	238	79704951
Infection	21.50	14.21	55	39144	241657	79463532
Skin hyperpigmentation	21.48	14.21	22	39177	7281	79697908
Thrombocytopenic purpura	21.45	14.21	14	39185	2455	79702734
Lichenoid keratosis	21.43	14.21	17	39182	4040	79701149
Wrong technique in product usage process	21.41	14.21	5	39194	73870	79631319
Breast discomfort	21.39	14.21	8	39191	416	79704773
Balance disorder	21.27	14.21	11	39188	98846	79606343
Systemic lupus erythematosus	21.26	14.21	17	39182	121132	79584057
Musculoskeletal pain	21.13	14.21	12	39187	102342	79602847
Pulmonary cavitation	21.10	14.21	12	39187	1644	79703545
Respiratory symptom	20.97	14.21	18	39181	4773	79700416
Biopsy liver abnormal	20.72	14.21	8	39191	454	79704735
Pruritus	20.71	14.21	290	38909	394358	79310831
Skin reaction	20.68	14.21	32	39167	16036	79689153
Injection site pain	20.64	14.21	20	39179	129818	79575371
Lymph node abscess	20.53	14.21	5	39194	57	79705132
Mast cell activation syndrome	20.48	14.21	9	39190	711	79704478
Pancreatitis	20.34	14.21	77	39122	68498	79636691
Dry mouth	20.15	14.21	9	39190	88010	79617179
Liver transplant	20.14	14.21	17	39182	4406	79700783
Haemolysis	20.08	14.21	28	39171	12784	79692405
Mastitis bacterial	20.07	14.21	5	39194	63	79705126
Nephropathy toxic	20.03	14.21	36	39163	20383	79684806
Clostridium difficile colitis	19.91	14.21	47	39152	32236	79672953
Coronary artery disease	19.85	14.21	4	39195	65470	79639719
Latent tuberculosis	19.78	14.21	15	39184	3338	79701851
Suicide attempt	19.75	14.21	8	39191	82924	79622265
Therapy naive	19.72	14.21	5	39194	68	79705121
Oropharyngeal pain	19.63	14.21	15	39184	109338	79595851
Rheumatoid factor positive	19.58	14.21	3	39196	59836	79645353
Palpitations	19.56	14.21	20	39179	126590	79578599
Testicular mass	19.46	14.21	5	39194	72	79705117
Limbal swelling	19.32	14.21	4	39195	20	79705169
Blood alkaline phosphatase increased	19.31	14.21	72	39127	63592	79641597
Toxic optic neuropathy	19.27	14.21	10	39189	1143	79704046
Anticoagulation drug level below therapeutic	19.24	14.21	11	39188	1522	79703667
Generalised onset non-motor seizure	19.14	14.21	5	39194	77	79705112
Gastrooesophageal reflux disease	19.10	14.21	14	39185	104232	79600957
Nasal congestion	18.87	14.21	7	39192	76545	79628644
Drug level abnormal	18.85	14.21	7	39192	357	79704832
C-reactive protein increased	18.72	14.21	118	39081	128909	79576280
Axonal neuropathy	18.72	14.21	12	39187	2042	79703147
Unmasking of previously unidentified disease	18.70	14.21	12	39187	2045	79703144
Chromaturia	18.70	14.21	40	39159	25706	79679483
Off label use	18.62	14.21	580	38619	906635	78798554
Drug level increased	18.53	14.21	52	39147	39599	79665590
Marrow hyperplasia	18.51	14.21	11	39188	1637	79703552
Stress	18.45	14.21	8	39191	79604	79625585
Antimicrobial susceptibility test resistant	18.41	14.21	7	39192	381	79704808
Type 2 diabetes mellitus	18.38	14.21	3	39196	57119	79648070
Splenomegaly	18.36	14.21	35	39164	20719	79684470
Purpura non-thrombocytopenic	18.31	14.21	6	39193	210	79704979
Skin odour abnormal	18.26	14.21	12	39187	2129	79703060
Vasculitis necrotising	18.14	14.21	10	39189	1290	79703899
Therapeutic product effect decreased	18.13	14.21	33	39166	163830	79541359
Tuberculous pleurisy	18.12	14.21	8	39191	639	79704550
Trichoglossia	17.98	14.21	8	39191	651	79704538
Renal failure	17.97	14.21	164	39035	200804	79504385
Acute respiratory distress syndrome	17.93	14.21	55	39144	44012	79661177
Pericarditis	17.83	14.21	15	39184	104221	79600968
Aspergillus infection	17.80	14.21	33	39166	19128	79686061
Subacute hepatic failure	17.77	14.21	6	39193	231	79704958
Type III immune complex mediated reaction	17.76	14.21	8	39191	670	79704519
Hypertension	17.75	14.21	93	39106	330899	79374290
Vanishing bile duct syndrome	17.73	14.21	11	39188	1767	79703422
Therapeutic agent-diagnostic test interaction	17.59	14.21	4	39195	33	79705156
Psoas abscess	17.52	14.21	9	39190	1008	79704181
Coagulation factor X level decreased	17.47	14.21	5	39194	110	79705079
Wheezing	17.38	14.21	19	39180	116645	79588544
Human herpesvirus 6 infection	17.31	14.21	17	39182	5353	79699836
Hilar lymphadenopathy	17.28	14.21	11	39188	1848	79703341
Hepatitis A virus test positive	17.28	14.21	4	39195	36	79705153
Cell death	17.28	14.21	16	39183	4683	79700506
Rash erythematous	17.24	14.21	65	39134	57704	79647485
Urinary tract inflammation	17.22	14.21	6	39193	254	79704935
Erythema multiforme	17.16	14.21	31	39168	17620	79687569
Cryptococcosis	17.10	14.21	14	39185	3479	79701710
Upper respiratory tract infection	17.02	14.21	12	39187	91156	79614033
Osteoarthritis	16.96	14.21	11	39188	87298	79617891
Anuria	16.90	14.21	34	39165	20929	79684260
Dyspnoea exertional	16.87	14.21	11	39188	87062	79618127
Chylothorax	16.74	14.21	8	39191	767	79704422
Hepatorenal syndrome	16.66	14.21	15	39184	4234	79700955
Human herpesvirus 7 infection	16.64	14.21	5	39194	131	79705058
Endocarditis bacterial	16.63	14.21	10	39189	1519	79703670
Post treatment Lyme disease syndrome	16.56	14.21	3	39196	6	79705183
Irritable bowel syndrome	16.55	14.21	5	39194	62236	79642953
Granulomatous lymphadenitis	16.52	14.21	6	39193	287	79704902
Tendon disorder	16.50	14.21	19	39180	7167	79698022
Rebound effect	16.42	14.21	19	39180	7207	79697982
Hyperglycaemia	16.40	14.21	7	39192	70328	79634861
Skin test positive	16.30	14.21	9	39190	1165	79704024
Septic embolus	16.30	14.21	11	39188	2040	79703149
Mobility decreased	15.98	14.21	22	39177	122153	79583036
Pulmonary granuloma	15.96	14.21	11	39188	2110	79703079
Candida infection	15.83	14.21	48	39151	38166	79667023
Joint tuberculosis	15.69	14.21	5	39194	160	79705029
Leprosy	15.60	14.21	5	39194	163	79705026
Chronic allograft nephropathy	15.60	14.21	10	39189	1701	79703488
Pseudomembranous colitis	15.46	14.21	16	39183	5358	79699831
Malabsorption from administration site	15.40	14.21	5	39194	170	79705019
Acid fast bacilli infection	15.37	14.21	5	39194	171	79705018
Injection site reaction	15.31	14.21	4	39195	54781	79650408
CD4/CD8 ratio decreased	15.29	14.21	4	39195	62	79705127
Crystalluria	15.19	14.21	8	39191	943	79704246
Speech disorder	15.17	14.21	4	39195	54441	79650748
Atypical mycobacterial lower respiratory tract infection	15.13	14.21	5	39194	180	79705009
Hypermetabolism	15.04	14.21	6	39193	372	79704817
Paradoxical pain	15.03	14.21	3	39196	12	79705177
Renal atrophy	15.01	14.21	10	39189	1815	79703374
Implant site infection	14.81	14.21	10	39189	1855	79703334
Vitamin K decreased	14.73	14.21	4	39195	72	79705117
Inappropriate schedule of product administration	14.70	14.21	27	39172	133601	79571588
Scar excision	14.68	14.21	4	39195	73	79705116
Skin plaque	14.67	14.21	22	39177	10723	79694466
Cardiac disorder	14.62	14.21	7	39192	65750	79639439
Optic atrophy	14.49	14.21	10	39189	1923	79703266
White blood cell count decreased	14.42	14.21	46	39153	188242	79516947
Disease recurrence	14.32	14.21	51	39148	44058	79661131
Synovial cyst	14.31	14.21	21	39178	10044	79695145
Pyroglutamic acidosis	14.26	14.21	8	39191	1068	79704121
Angina bullosa haemorrhagica	14.26	14.21	5	39194	216	79704973
Visual pathway disorder	14.24	14.21	4	39195	82	79705107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AB02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics
ATC	J04AM02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04BA50	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF LEPRA Drugs for treatment of lepra
ATC	J04BA51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF LEPRA Drugs for treatment of lepra
FDA CS	M0019113	Rifamycins
FDA EPC	N0000175500	Rifamycin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000904	Antibiotics, Antitubercular
MeSH PA	D000995	Antitubercular Agents
MeSH PA	D065695	Cytochrome P-450 CYP2B6 Inducers
MeSH PA	D065697	Cytochrome P-450 CYP2C19 Inducers
MeSH PA	D065696	Cytochrome P-450 CYP2C8 Inducers
MeSH PA	D065698	Cytochrome P-450 CYP2C9 Inducers
MeSH PA	D065701	Cytochrome P-450 CYP3A Inducers
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D007917	Leprostatic Agents
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
CHEBI has role	CHEBI:33231	antitubercular agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35816	leprostatic drugs
CHEBI has role	CHEBI:37416	RNA polymerase inhibitors
CHEBI has role	CHEBI:48001	protein synthesis inhibitors
CHEBI has role	CHEBI:48422	angiogenesis antagonist
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:77318	PXR agonists
CHEBI has role	CHEBI:171664	antiamoebic drugs
CHEBI has role	CHEBI:176497	geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Inactive tuberculosis	indication	11999007
Acute tuberculosis	indication	25629007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Meningococcus carrier	indication	170486006
Prevention of Meningococcal Meningitis	indication
Inhalational anthrax	off-label use	11389007
Staphylococcal infectious disease	off-label use	56038003
Leprosy	off-label use	81004002	DOID:1024
Cutaneous anthrax	off-label use	84980006	DOID:7426
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Atypical mycobacterial infection	off-label use	111812000
Anthrax	off-label use	409498004	DOID:7427
Multibacillary leprosy	off-label use	416257001
Paucibacillary leprosy	off-label use	416483009
Single Lesion Paucibacillary Leprosy	off-label use
Haemophilus B Influenzae Prevention	off-label use
Synergy for Staphylococcal Osteomyelitis	off-label use
Nutritional disorder	contraindication	2492009	DOID:374
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Jaundice	contraindication	18165001
Depressive disorder	contraindication	35489007
Acute hepatitis	contraindication	37871000
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Gout	contraindication	90560007	DOID:13189
Anemia due to enzyme deficiency	contraindication	111577008
Pancytopenia	contraindication	127034005	DOID:12450
Acute hepatic failure	contraindication	197270009
Non-infective meningitis	contraindication	230155003
Disease of liver	contraindication	235856003	DOID:409
Diabetic - poor control	contraindication	268519009
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Peripheral nerve disease	contraindication	302226006
Neutropenic disorder	contraindication	303011007	DOID:1227
Aplastic anemia	contraindication	306058006	DOID:12449
Porphyria	contraindication	418470004
Diabetic peripheral neuropathy	contraindication	424736006
Slow acetylator due to N-acetyltransferase enzyme variant	contraindication	425079005
Prolonged-Severe Nausea and Vomiting	contraindication
Chronic Hepatic Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.94	acidic
pKa2	7.23	acidic
pKa3	11.03	acidic
pKa4	11.77	acidic
pKa5	12.55	acidic
pKa6	7.83	Basic
pKa7	1.35	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.25	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	4.95	CHEMBL
Caspase-1	Enzyme	P29466	CASP1_HUMAN		IC50	5.08	DRUG MATRIX
Solute carrier organic anion transporter family member 1B1	Transporter	Q9Y6L6	SO1B1_HUMAN	INHIBITOR	Ki	5.96	IUPHAR
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	4.52	CHEMBL
Solute carrier organic anion transporter family member 1A2	Transporter	P46721	SO1A2_HUMAN	INHIBITOR	Ki	4.29	IUPHAR
Solute carrier organic anion transporter family member 1B3	Transporter	Q9NPD5	SO1B3_HUMAN	INHIBITOR	IC50	5.80	IUPHAR
Glutathione S-transferase omega-1	Unclassified	P78417	GSTO1_HUMAN		IC50	4.12	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	5.64	CHEMBL
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	5.15	CHEMBL
DNA-directed RNA polymerase subunit beta	Enzyme		RPOB_ECOLI	INHIBITOR			DRUGBANK	CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH]	Enzyme		INHA_MYCTU		IC50	7.52	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.53	DRUG MATRIX
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.46	CHEMBL

External reference:

ID	Source
4018619	VUID
N0000146932	NUI
D00211	KEGG_DRUG
4018619	VANDF
CHEBI:28077	CHEBI
RFP	PDB_CHEM_ID
CHEMBL374478	ChEMBL_ID
2765	IUPHAR_LIGAND_ID
DB01045	DRUGBANK_ID
202953	RXNORM
1197	MMSL
1207	MMSL
5424	MMSL
d00047	MMSL
002789	NDDF
29175007	SNOMEDCT_US
387159009	SNOMEDCT_US
C0035608	UMLSCUI
D012293	MESH_DESCRIPTOR_UI
135398735	PUBCHEM_CID
2323	INN_ID
VJT6J7R4TR	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rifadin	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0508	CAPSULE	300 mg	ORAL	NDA	27 sections
Rifadin	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0510	CAPSULE	150 mg	ORAL	NDA	27 sections
Rifadin IV	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0597	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifadin IV	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0597	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifadin IV	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0597	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifadin IV NOVAPLUS	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0599	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifadin IV NOVAPLUS	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0599	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifadin IV NOVAPLUS	HUMAN PRESCRIPTION DRUG LABEL	1	0068-0599	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	NDA	27 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9230	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	ANDA	26 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0799	CAPSULE	300 mg	ORAL	ANDA	24 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0799	CAPSULE	300 mg	ORAL	ANDA	24 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0801	CAPSULE	150 mg	ORAL	ANDA	24 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0801	CAPSULE	150 mg	ORAL	ANDA	24 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1315	CAPSULE	300 mg	ORAL	ANDA	21 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1315	CAPSULE	300 mg	ORAL	ANDA	21 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1393	CAPSULE	150 mg	ORAL	ANDA	21 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1393	CAPSULE	150 mg	ORAL	ANDA	21 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5282	CAPSULE	300 mg	ORAL	ANDA	24 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5282	CAPSULE	300 mg	ORAL	ANDA	24 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-151	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	ANDA	25 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-151	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	600 mg	INTRAVENOUS	ANDA	25 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-527	CAPSULE	300 mg	ORAL	ANDA	21 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	24658-801	CAPSULE	150 mg	ORAL	ANDA	22 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	24658-802	CAPSULE	300 mg	ORAL	ANDA	22 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-039	CAPSULE	300 mg	ORAL	ANDA	26 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	42806-799	CAPSULE	300 mg	ORAL	ANDA	22 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	42806-799	CAPSULE	300 mg	ORAL	ANDA	22 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	42806-801	CAPSULE	150 mg	ORAL	ANDA	22 sections
RIFAMPIN	HUMAN PRESCRIPTION DRUG LABEL	1	42806-801	CAPSULE	150 mg	ORAL	ANDA	22 sections
Rifampin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0964	CAPSULE	300 mg	ORAL	ANDA	25 sections